Clinical Trial Update: Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of GSK's meningococcal B recombinant vaccine given with routine vaccines to healthy infants starting at 2 mont…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal B Recombinant Vaccine (Meningococcal B recombinant vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningococcal Disease, Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-06-15